RxDoctor Payments DataLook up a doctor →

Raymond Fink

Endocrinology, Diabetes & Metabolism · la Mesa, CANPI 1164414652

Payments from drug & device makers

$376,019in general payments, 2019–2025

Across 1,009 payments — averaging $372.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$274K
  • Eli Lilly$69K
  • Dexcom, Inc.$22K
  • Chiasma, Inc.$8K
  • Sanofi-aventis U.S. LLC$357
  • Amgen$342
  • plus $2K from 18 others
$7,161in research payments, 2019–2025

Across 4 payments — averaging $1790.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Food & beverage$2,23398%
  • Education$422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$376,019 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Other endocrinology, diabetes & metabolism in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →